Compugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short Interest

Compugen Ltd. (NASDAQ:CGEN) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,880,000 shares, a growth of 15.3% from the August 31st total of 1,630,000 shares. Based on an average daily volume of 256,200 shares, the short-interest ratio is currently 7.3 days.

Compugen Trading Up 3.1 %

Shares of CGEN stock traded up $0.05 on Friday, hitting $1.81. 345,230 shares of the stock were exchanged, compared to its average volume of 436,472. The firm has a market capitalization of $161.08 million, a P/E ratio of -9.50 and a beta of 2.65. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The business has a 50-day moving average of $1.85 and a 200 day moving average of $2.01.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.06. The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.68 million. During the same quarter in the prior year, the business earned ($0.11) EPS. As a group, research analysts forecast that Compugen will post 0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Institutional Investors Weigh In On Compugen

Institutional investors have recently made changes to their positions in the stock. Rothschild Investment LLC bought a new stake in Compugen during the second quarter worth $380,000. ARK Investment Management LLC increased its holdings in shares of Compugen by 4.7% during the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after buying an additional 48,979 shares in the last quarter. Secure Asset Management LLC acquired a new stake in Compugen in the second quarter valued at $69,000. Squarepoint Ops LLC increased its holdings in Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 16,253 shares during the period. Finally, Heron Bay Capital Management acquired a new stake in Compugen in the first quarter valued at $32,000. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.